In the EAE model of MS, IFN-γ functions as a pro-inflammatory cytokine in the early stages of disease [10], [11], [26], yet it also assumes a prominent anti-inflammatory role during the transition to remission [10], [12]–[15]. Here, IFNG is linked to myeloid sarcoma.